Background Image
Table of Contents Table of Contents
Previous Page  49 / 78 Next Page
Show Menu
Previous Page 49 / 78 Next Page
Page Background

NCCN Guidelines for Patients


Soft Tissue Sarcoma, Version 1.2014


For widespread cancer growth, options are to

increase the dose of imatinib or start taking sunitinib.

After the new treatment, your doctors will assess if

the treatment is working with CT or MRI. PET may be

used if CT or MRI results are unclear.

Joining a clinical trial is highly encouraged. You’ll

likely receive the best management of care. Ask your

treatment team if there are clinical trials you can join.

Chart 4.3.2

lists treatment options if the cancer

keeps growing while taking imatinib or sunitinib.

There are four treatment options. Taking regorafenib

is strongly supported. You may also join a clinical trial

or start alternate treatment. However, less research

has been done to know if the alternate treatments will

be helpful. The fourth option is to receive supportive

care to relieve any discomfort you may have. As

part of supportive care, you should continue to take

imatinib or another drug even if your tumor is growing.

The tumor will grow more slowly on some treatment

than on none.


Gastrointestinal stromal tumors Treatment after progression